Amenorrhea is considered a type of abnormal menstrual bleeding characterized by the unexpected absence of menstrual bleeding, lasting three months or longer. Menstrual bleeding typically happens approximately once a month when blood and endometrial tissue, or tissue lining the inside of the uterus, sheds from the uterus through the vagina. Menstruation is expected to stop with pregnancy, breastfeeding, and menopause, or the natural cessation of the menstrual cycle at an older age. However, women may also experience amenorrhea because of an underlying health condition, including low body weight or polycystic ovarian syndrome, that may complicate fertility and contribute to decreased quality of life. According to the American College of Obstetricians and Gynecologists, one in twenty-five women experience amenorrhea as a menstrual disorder within their lives at times.

The NuvaRing is a self-administered hormonal contraceptive device in the form of a flexible plastic ring that is inserted into the vagina. It releases the hormones etonogestrel and ethinylestradiol, which are synthetic forms of the female reproductive hormones progesterone and estrogen, respectively. The pharmaceutical company Organon first made NuvaRing in the Netherlands in 1980s. The Netherlands first approved it for use in February of 2001, and the United States did the same in October of that year. To insert the NuvaRing, a user pinches the ring together to compress it and inserts it into the vaginal canal, where its exact placement does not matter. The NuvaRing stays in the vagina for three weeks, after which the user removes it for one week. During the week following removal, the user experiences bleeding similar to a menstrual period. The NuvaRing was one of the first monthly vaginal rings used for contraception, and it provides a self-administered method of birth control, which can be more accessible for some users than taking a birth control pill every day.

In 2012, Stephen Sidney, T. Craig Cheetham, Frederick A. Connell, and colleagues published “Recent Combined Hormonal Contraceptives (CHCs) and the Risk of Thromboembolism and Other Cardiovascular Events in New Users,” hereafter “Combined Hormonal Contraceptives” in Contraception. The authors gathered records of major cardiovascular events in patients who were using combined hormonal contraceptive treatments, or CHCs. A CHC is a birth control medication that contains both estrogen and progestin hormones. The CHCs of focus, which the authors referred to as the study CHCs, included a pill, patch, and vaginal ring that the US Food and Drug Administration, or FDA, recently approved at the time of publication. The researchers compared the rates of cardiovascular events between users of the study CHCs to users of established CHCs to find any increased cardiovascular risk. “Combined Hormonal Contraceptives” showed that the study CHCs did come with some increased cardiovascular risk, and reconfirmed the known cardiovascular risks of CHCs in general, providing safety information for people who may want to start birth control.

On 22 March 1972, in Eisenstadt v. Baird, hereafter Eisenstadt, the United States Supreme Court determined, in a six to one decision, that unmarried individuals have the same right to access contraceptives as married couples. Eisenstadt involved William Baird, a reproductive rights advocate who intentionally broke Massachusetts law in 1967 by giving a speech about birth control at Boston University in Boston, Massachusetts, and giving an unmarried, nineteen-year-old woman contraceptives. Baird argued that laws against unmarried people accessing contraceptives unfairly discriminated against unmarried people and denied them reproductive autonomy. Massachusetts law, however, stated that contraceptives could only be distributed by medical professions to married people. The case followed a similar legal challenge from 1965, Griswold v. Connecticut, hereafter Griswold, which found that married individuals have the right to access contraceptives based on a constitutional right to privacy in the US. Eisenstadt reinforced the constitutional right to privacy and equalized the accessibility to contraceptives for married and single individuals.